ID | 1255 |
Name of the vaccine | GSK217744 |
Microbe | Bacteria |
Disease name | Diphtheria |
Name of bacteria | Corynebacterium diphtheriae |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | 12 to 15 months |
Description of the vaccine | DTPa-HBV-IPV/Hib vaccine. |
Name of the manufacturer | GlaxoSmithKline |
Name of the manufacturing country | Dominican Republic, Finland |
Year of manufacture | 2012 |
Clinical Phase status | Clinical - Phase 2 |
Bacterial strain | Gram-positive bacillus. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Primary vaccination at 2, 3 and 4 months and a booster dose. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | For acellular pertussis, tetanus, hepatitis B, poliomyelitis and haemophilus influenzae type b. |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination (4 doses) |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT01453998 |
Reference | NA |
Other name | NA |
Additional Links | NA
|